Heart Failure Patients
Conditions
Interventions
None listed
Sponsors
Kawaguchi Cardiovascular and Respiratory Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients diagnosed with heart failure according to the Heart Failure Management Guidelines (JCS/JHFS 2025) 2) Patients with a serum NT-proBNP level of 300 pg/mL or higher at the time of consent acquisition 3) Patients for whom written consent for study participation has been obtained from the patient or a legal representative 4) Patients aged 20 years or older
Exclusion criteria
Exclusion criteria: 1) Patients whose bed or futon may be used for sleeping by individuals other than the study subject or by pets 2) Patients who, due to lifestyle factors, cannot undergo regular respiratory monitoring for at least 2 hours per night on 3 or more days per week 3) Patients without spontaneous breathing 4) Patients receiving treatment for chronic obstructive pulmonary disease (COPD) 5) Patients receiving assisted ventilation therapy such as Adaptive Servo-Ventilation (ASV) or Continuous Positive Airway Pressure (CPAP) therapy during sleep 6) Pregnant patients 7) Patients whose primary diagnosis is Obstructive Sleep Apnea Syndrome (OSAS) 8) Patients receiving guidance management using information from an implantable cardiac pacemaker or implantable cardioverter-defibrillator (ICD) 9) Patients with a history of cerebral hemorrhage or cerebral infarction, regardless of presence of sequelae 10) Patients undergoing dialysis therapy for renal failure or scheduled to start during the observation period 11) Patients currently participating in interventional studies (including clinical trials) 12) Patients for whom follow-up during the observation period is not feasible 13) Besides the above, patients deemed inappropriate by the physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sensitivity of RST reduction during the period from 60 to 14 days prior to the onset date for cases of worsening heart failure where clinically significant objective findings deteriorate alongside worsening heart failure symptoms and signs. | — |
Countries
Japan
Contacts
Public ContactResearch Administration Office Contact person
A2 Healthcare Corporation Clinical Development Division
Outcome results
None listed